Extended Duration Counseling for Tobacco Addiction

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Tobacco Addiction+1 More
Extended Duration Behavioral Smoking Cessation Counseling - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to determine if extending the behavioral smoking-cessation treatment period to one year will significantly improve cessation outcomes among those planning a quit attempt.

Eligible Conditions
  • Tobacco Addiction

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Tobacco Addiction

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: One year

One year
Proportion of subjects abstinent by treatment group at 1 year post-cessation.
Two years
Proportion of subjects abstinent by treatment group at 2 years post-cessation.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Tobacco Addiction

Trial Design

3 Treatment Groups

Extended Duration Counseling
1 of 3
Moderate Duration Counseling
1 of 3
Brief-Duration Counseling
1 of 3
Active Control
Non-Treatment Group

450 Total Participants · 3 Treatment Groups

Primary Treatment: Extended Duration Counseling · Has Placebo Group · Phase 4

Extended Duration Counseling
Behavioral
ActiveComparator Group · 1 Intervention: Extended Duration Behavioral Smoking Cessation Counseling · Intervention Types: Behavioral
Brief-Duration Counseling
Behavioral
PlaceboComparator Group · 1 Intervention: Extended Duration Behavioral Smoking Cessation Counseling · Intervention Types: Behavioral
Moderate Duration Counseling
Behavioral
ActiveComparator Group · 1 Intervention: Extended Duration Behavioral Smoking Cessation Counseling · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one year

Who is running the clinical trial?

Harvard University Faculty of MedicineLead Sponsor
12 Previous Clinical Trials
22,886 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,225 Previous Clinical Trials
5,612,477 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.